"Intrathecal use of gadolinium-based contrast agents (GBCAs), for example, in MR cisternography or MR myelography, is not approved by regulatory agencies such as the FDA, and as such, its use is considered off-label."
"At higher doses (over 1 mmol), intrathecal administration of GBCAs can lead to serious adverse events, including but not limited to neurological signs and symptoms (e.g. altered mental state, dysarthria, ataxia, seizures, vertigo) as well as cardiovascular and respiratory symptoms 1,2. Rarely, and particularly at much higher doses, status epilepticus, coma and even death have been reported 1,2."
"At higher doses (over 1 mmol), intrathecal administration of GBCAs can lead to serious adverse events, including but not limited to neurological signs and symptoms (e.g. altered mental state, dysarthria, ataxia, seizures, vertigo) as well as cardiovascular and respiratory symptoms 1,2. Rarely, and particularly at much higher doses, status epilepticus, coma and even death have been reported 1,2."